NCT05774561
Role of Liquid Biopsies in HPV-associated Cancer Treatment Monitoring
At risk: Primary completion moved 12 months later.
See at-risk trials from The Institute of Molecular and Translational Medicine, Czech Republic
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 3 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary completion pushed from May 31, 2026 to May 31, 2027
- Study completion pushed from Dec 1, 2026 to Dec 1, 2027
- Study description revised
- Notable Phase: Not applicable to Not specifiedv4
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Arms and interventions
In total, approx. 200 OPC cancer patients will be enrolled in the study Arm A, with both prospective and retrospective parts enrolling 100 OPC patients. The Arm A will enroll patients from the Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital Olomouc. Pre-treatment primary samples of fresh or FFPE tissue samples will be collected. Liquid biopsies (gargle lavage, oropharyngeal smear, breath condensate, and blood sample) will be collected. Obtained samples will be tested by CE-IVD (device complies with European in vitro diagnostic Directive) marked HPV diagnostic test. A laboratory developed digital droplet PCR assay will be used for ct HPV DNA detection. Sampling will be performed at pre \& post treatment check-ups, and every 3 months for 3 years and every 6 months for 2 years.
Into the study Arm B will be enrolled 80 patients with CC and 120 patients with HSIL, and 80 patients will be enrolled into the retrospective part. The Arm B will enroll patients from the Department of Gynecology and Obstetrics, University Hospital Olomouc. Pre-treatment primary samples of fresh or FFPE tissue samples will be collected. Liquid biopsies (cervicovaginal swab and blood sample) will be collected. Obtained samples will be tested by CE-IVD marked HPV diagnostic test. A laboratory developed digital droplet PCR assay will be used for ct HPV DNA detection. Sampling will be performed at pre \& post treatment check-ups, and every 3 months for 2 years and every 6 months for 3 years.
Diagnostic tests: Arm A - Diagnostic test: HPV detection in liquid biopsies, Arm B - Diagnostic test: HPV detection in liquid biopsies
Sites
1 site in 1 country
- University Hospital OlomoucOlomouc, Czechia